Filtered By:
Source: Journal of Thrombosis and Haemostasis
Condition: Thrombosis
This page shows you your search results in order of date. This is page number 2.
Order by Relevance | Date
Total 137 results found since Jan 2013.
Dissociation between the pharmacokinetics and pharmacodynamics of once ‐daily rivaroxaban and twice‐daily apixaban: a randomized crossover study
ConclusionsDespite similar exposure to both drugs, rivaroxaban 20 mg once daily was associated with greater and more sustained inhibition of thrombin generation than apixaban 5 mg twice daily. Sensitive prothrombin time and activated partial thromboplastin time assays can be used to estimate the anticoagulant effects of rivaroxaban.This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - August 1, 2017 Category: Hematology Authors: Reinhold Kreutz, Pontus B. Persson, Dagmar Kubitza, Kirstin Thelen, Stefan Heitmeier, Stephan Schwers, Michael Becka, Melanie Hemmrich Tags: Original Article ‐ Coagulation Source Type: research
C ‐reactive protein gene polymorphism predicts the risk of thromboembolic stroke in patients with atrial fibrillation: a more than 10‐year prospective follow‐up study
ConclusionThe CRP triallelic polymorphism and the CRP level are associated with the risk of incident thromboembolic stroke in patients with AF.
Source: Journal of Thrombosis and Haemostasis - July 14, 2017 Category: Hematology Authors: S. ‐N. Chang, L.‐P. Lai, F.‐T. Chiang, J.‐L. Lin, J.‐J. Hwang, C.‐T. Tsai Tags: Original Article Source Type: research
Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura
ConclusionIn total, 11.4% of caplacizumab‐treated patients and 43.2% of placebo‐treated patients experienced one or more major thromboembolic events, experienced an exacerbation, or died. This analysis shows the potential for caplacizumab to reduce the risk of major thromboembolic morbidities and mortality associated with aTTP.
Source: Journal of Thrombosis and Haemostasis - June 5, 2017 Category: Hematology Authors: F. Peyvandi, M. Scully, J. A. Kremer Hovinga, P. Kn öbl, S. Cataland, K. De Beuf, F. Callewaert, H. De Winter, R. K. Zeldin Tags: Brief Report Source Type: research
Assessment of clinically relevant bleeding as a surrogate outcome for major bleeding: validation by meta ‐analysis of randomized controlled trials
ConclusionDespite an apparent correlation between CRB and major bleeding in major orthopedic surgery, AF and for double‐blind acute VTE studies, the wide CIs suggest that CRB might not be an acceptable surrogate outcome in any of these settings.This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - May 1, 2017 Category: Hematology Authors: S. Laporte, C. Chapelle, L. Bertoletti, E. Ollier, P. Zufferey, J ‐C Lega, A. Merah, H. Décousus, S. Schulman, G. Meyer, M. Cucherat, P. Mismetti Tags: Original Article ‐ Clinical Haemostasis and Thrombosis Source Type: research
The C ‐reactive protein gene polymorphism predicts the risk of thromboembolic stroke in atrial fibrillation: a more than 10‐year prospective follow‐up study
ConclusionThe CRP gene triallelic polymorphism and the CRP level are associated with the risk of incident thromboembolic stroke in patients with AF.This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - May 1, 2017 Category: Hematology Authors: Sheng ‐Nan Chang, Ling‐Ping Lai, Fu‐Tien Chiang, Jiunn‐Lee Lin, Juey‐Jen Hwang, Chia‐Ti Tsai Tags: Original Article ‐ Cardiovascular Medicine Source Type: research
Caplacizumab reduces the frequency of major thromboembolic events, exacerbations, and death in patients with acquired thrombotic thrombocytopenic purpura
ConclusionIn total, 11.4% of caplacizumab‐treated patients versus 43.2% of placebo‐treated patients experienced one or more major thromboembolic event, an exacerbation or died. This analysis shows the potential for caplacizumab to reduce the risk of major thromboembolic morbidities and mortality associated with aTTP.This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - April 26, 2017 Category: Hematology Authors: F. Peyvandi, M. Scully, J. A. Kremer Hovinga, P. Kn öbl, S. Cataland, K. De Beuf, F. Callewaert, H. De Winter, R. K. Zeldin Tags: Brief Report ‐ Clinical Haemostasis and Thrombosis Source Type: research
Associations of coagulation factors IX and XI levels with incident coronary heart disease and ischemic stroke: the REGARDS study
ConclusionsHigher FIX antigen was associated with incident CHD in blacks but not whites. FIX levels may increase CHD risk among blacks.This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - April 10, 2017 Category: Hematology Authors: N.C. Olson, M. Cushman, S.E. Judd, B.M. Kissela, M.M. Safford, G. Howard, N.A. Zakai Tags: Original Article ‐ Coagulation Source Type: research
Shear ‐sensitive nanocapsule drug release for site‐specific inhibition of occlusive thrombus formation
ConclusionsTargeted delivery of eptifibatide by shear‐sensitive nanocapsules offers site‐specific antiplatelet potential, and may form a basis for developing more potent and safer antiplatelet drugs.
Source: Journal of Thrombosis and Haemostasis - April 9, 2017 Category: Hematology Authors: C. P. Molloy, Y. Yao, H. Kammoun, T. Bonnard, T. Hoefer, K. Alt, F. Tovar ‐Lopez, G. Rosengarten, P. A. Ramsland, A. D. Meer, A. Berg, A. J. Murphy, C. E. Hagemeyer, K. Peter, E. Westein Tags: Original Article Source Type: research
Predictive performance of the CHA2DS2 ‐VASc rule in atrial fibrillation: a systematic review and meta‐analysis
ConclusionsStudies validating CHA2DS2‐VASc demonstrate high heterogeneity in predicted stroke risks for different scores.This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - April 1, 2017 Category: Hematology Authors: Sander van Doorn, Thomas P.A. Debray, Femke Kaasenbrood, Arno W. Hoes, Frans H. Rutten, Karel G.M. Moons, Geert ‐Jan Geersing Tags: Original Article ‐ Cardiovascular Medicine Source Type: research
A First ‐in‐human Study of DS‐1040, an Inhibitor of the Activated Form of Thrombin‐Activatable Fibrinolysis Inhibitor, in Healthy Subjects
ConclusionsThe novel fibrinolysis‐enhancing agent DS‐1040 has favorable PK/PD properties and safety profile, which warrants further clinical development.This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - January 31, 2017 Category: Hematology Authors: Jin Zhou, Jarema Kochan, Ophelia Yin, Vance Warren, Cynthia Zamora, George Atiee, Joseph Pav, Yasushi Orihashi, Vijay Vashi, Victor Dishy Tags: Original Article ‐ Fibrinolysis Source Type: research
Maresin 1 induces a novel pro ‐resolving phenotype in human platelets
ConclusionsThese data support the concept that SPMs differentially regulate platelet function and may represent a novel class of antiplatelet agents. SPMs also may play an important role in the resolution of inflammation in cardiovascular diseases.This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - January 11, 2017 Category: Hematology Authors: Katie L. Lannan, Sherry L. Spinelli, Neil Blumberg, Richard P. Phipps Tags: Original Article ‐ Platelets Source Type: research
The effect of correcting VerifyNow P2Y12 assay results for hematocrit in patients undergoing percutaneous coronary interventions
ConclusionCorrecting PRU for HCT does not improve the prediction of thrombotic events following PCI.This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - December 31, 2016 Category: Hematology Authors: P.W.A. Janssen, T.O. Bergmeijer, T.C. Godschalk, T.T.D. Le, N.J. Breet, J.C. Kelder, C.M. Hackeng, J.M. ten Berg Tags: Original Article ‐ Platelets Source Type: research
Filaggrin loss ‐of‐function mutations as risk factors for ischemic stroke in the general population
ConclusionIn this study of 97,174 individuals from the Danish general population, FLG loss‐of‐function mutations were associated with increased ischemic stroke risk; however, residual confounding is a possibility.This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - December 31, 2016 Category: Hematology Authors: Anette Varbo, B ørge G. Nordestgaard, Marianne Benn Tags: Original Article ‐ Cardiovascular Medicine Source Type: research
Association of Stroke Risk Biomarkers with Stroke Symptoms: The Reasons for Geographic And Racial Differences in Stroke Cohort
ConclusionsStrong associations of stroke risk biomarkers with stroke symptoms in persons without a clinical history of cerebrovascular disease support a hypothesis that some of these stroke symptoms represent unrecognized cerebrovascular disease. Future work is needed to determine whether these biomarkers identify persons with stroke symptoms who have a particularly high stroke risk.This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - November 3, 2016 Category: Hematology Authors: K. K. Landry, K. S. Alexander, N. A. Zakai, S. E. Judd, D. O. Kleindorfer, V. J. Howard, G. Howard, M. Cushman Tags: Original Article ‐ Cardiovascular Medicine Source Type: research
Optimizing stroke prevention in elderly patients with atrial fibrillation
Source: Journal of Thrombosis and Haemostasis - October 2, 2016 Category: Hematology Authors: G. Y. H. Lip Tags: Commentary Source Type: research
